Azalea Therapeutics launches with $82M to pioneer in vivo precision genomic medicines

Berkeley, CA, November 4, 2025 (Globe Newswire) -- Azalea Therapeutics has launched with $82 million in seed and Series A funding led by Third Rock Ventures to advance its Enveloped Delivery Vehicle (EDV) platform for in vivo cell engineering. Founded by CRISPR pioneer Jennifer Doudna and colleagues, Azalea’s technology enables cell-specific delivery and gene insertion directly inside patients, eliminating the need for ex vivo manufacturing. The company plans to develop in vivo CAR-T therapies for B cell cancers, autoimmune diseases, and multiple myeloma, marking a major step toward next-generation genomic medicine.

Read full article here.